Internal Medicine
06 Jan 2024 16:26
💢 تأثیر داروهای GLP1A بر سیر طبیعی آرتروز زانو
سال‌هاست که محققان در پی کشف دارویی برای تغییر سر طبیعی آرتروز هستند. بعید نیست داروهای جدید چاقی کلید حل این معما باشند!
👇
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423473/pdf/ard-2023-223845.pdf
🆔 @
.
Читать полностью…
Internal Medicine
05 Jan 2024 09:04
📍عصرانه این هفته:
انتقال فرآورده‌های خونی
📍با حضور:
دکتر سعید محمدی
دانشیار دانشگاه علوم پزشکی تهران
دکترای تخصصی هماتولوژی آزمایشگاهی و بانک خون
فلوشیپ علوم آزمایشگاهی بالینی
معاون فنی و فن آوری‌های نوین سازمان انتقال خون ایران
🗓 جمعه پانزدهم دی ماه
⏰ ساعت پنج و نیم عصر
تزریق خون و فرآورده‌های آن از زمان ابداع تا کنون، جان بسیاری از افراد را نجات داده است. با این وجود، خطرات خاص خود را نیز بر بیماران تحمیل می‌کند که بعضاً حتی می‌توانند کشنده باشند. در این عصرانه می‌خواهیم با نحوه درخواست صحیح خون و فرآورده‌های آن آشنا شویم نا از میزان این عوارض بکاهیم.
🔗 لینک برنامه عصرانه
👈 در تقویم گوگل ثبت کنید
برنامه به صورت لایو در اینستاگرام هم پخش خواهد شد،
اما توصیه ما فعلا شرکت از طریق Google meet است.
شرکت برای عموم آزاد است.
🔥🔥در پادکست عصرانه صوت عصرانه های قبلی را گوش کنید🔥🔥
این پست را برای هر کسی که سلامتی‌اش برای شما مهم است ارسال کنید.
#آگاهتر_سالمتر
#عصرانه
#بارش
🌧 بارش، گروهی برای آموزش
.
Читать полностью…
Internal Medicine
02 Jan 2024 22:37
💢 What Is Myasthenia Gravis?
🆔 @
.
Читать полностью…
Internal Medicine
22 Dec 2023 00:23
💢 Weight Loss Drug Zepbound Now Available in US Pharmacies
Zepbound (tirzepatide) is now available for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity); or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
Zepbound contains tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The approval was based on data from two 72-week, double-blind, placebo-controlled, phase 3 trials: SURMOUNT-1 (ClinicalTrials.gov Identifier: NCT04184622) and SURMOUNT-2 (ClinicalTrials.gov Identifier: NCT04657003). Findings from both studies showed significant reductions in body weight among patients treated with Zepbound compared with placebo.
🆔 @
.
Читать полностью…
Internal Medicine
20 Dec 2023 17:10
💢 Blood pressure remains largest contributor to global CVD; mortality on the rise
Global CV mortality and the prevalence of important cardiometabolic risk factors increased through 2022, with high BP remaining the strongest contributor, according to the 2023 update to the Global Burden of Disease special report on CVD.
👇
https://www.healio.com/news/cardiology/20231211/bp-remains-largest-contributor-to-global-cvd-mortality-on-the-rise
🆔 @
.
Читать полностью…
Internal Medicine
20 Dec 2023 14:36
💢 Three-quarters of patients in RA remission flare within 3 years of TNF inhibitor taper
Meanwhile, just 15% of patients in RA remission who remained on stable TNF inhibition demonstrated flare during the same time period.
👇
https://www.healio.com/news/rheumatology/20231219/threequarters-of-patients-in-ra-remission-flare-within-3-years-of-tnf-inhibitor-taper
🆔 @
.
Читать полностью…
Internal Medicine
18 Dec 2023 22:24
💢 The First Positive Randomized Trial for Long COVID
Last week researchers in Hong Kong published a randomized, double-blind, placebo-controlled trial of a gut microbiome intervention in 463 participants with Long Covid. This “synbiotic” preparation of combined pre- and probiotics, consisted of a “micro-encapsulated lyophilised powder containing 20 billion colony-forming units of three bacterial strains, B adolescentis, Bifidobacterium bifidum, and Bifidobacterium longum with three prebiotic compounds including galacto-oligosaccharides, xylo-oligosaccharides, and resistant dextrin.” It provided symptomatic relief at 6 months across most of the common and important symptoms of Long Covid.
The benefit derived was incomplete, since the alleviation of symptoms (the primary endpoint) was not accompanied by improvement in overall quality of life as assessed subjectively. So even if this welcome positive trial paves the way for gut microbiome manipulation, it is unlikely to be enough on its own.
🆔 @
.
Читать полностью…
Internal Medicine
14 Dec 2023 22:44
🔥
💢 Vitamin D supplements do not prevent bone fractures in children
A major clinical trial led by Queen Mary University of London and the Harvard T.H. Chan School of Public Health has found that vitamin D supplements do not increase bone strength or prevent bone fractures in children with vitamin D deficiency. The findings challenge widely held perceptions relating to the effects of vitamin D on bone health.
Clinical trials designed to test whether vitamin D supplements can prevent bone fractures in children have not previously been conducted.
The study, published in Lancet Diabetes & Endocrinology, is the largest randomised controlled trial of vitamin D supplementation ever conducted in children. Over the course of three years, 8,851 schoolchildren aged 6-13 living in Mongolia received a weekly oral dose of vitamin D supplementation.
95.5% of participants had vitamin D deficiency at baseline, and study supplements were highly effective in boosting vitamin D levels into the normal range.
However, they had no effect on fracture risk or on bone strength, measured in a subset of 1,438 participants using quantitative ultrasound.
The trial findings are likely to prompt scientists, doctors and public health specialists to re-consider the effects of vitamin D supplements on bone health.
The absence of any effect of sustained, generous vitamin D supplementation on fracture risk or bone strength in vitamin D deficient children is striking. In adults, vitamin D supplementation works best for fracture prevention when calcium is given at the same time -- so the fact that we did not offer calcium alongside vitamin D to trial participants may explain the null findings from this study.
It is also important to note that children who were found to have rickets during screening for the trial were excluded from participation, as it would not have been ethical to offer them placebo (dummy medication).
Thus, our findings only have relevance for children with low vitamin D status who have not developed bone complications. The importance of adequate vitamin D intake for prevention of rickets should not be ignored.
👉 Full-Text
🆔 @
.
Читать полностью…
Internal Medicine
14 Dec 2023 16:26
💢 Semaglutide and Cardiovascular Outcomes in Obesity
The GLP-1 receptor agonist semaglutide can reduce adverse cardiovascular events in patients with diabetes. Whether this effect extends to patients with overweight or obesity, but without diabetes, is unknown.
New research findings are summarized in a short video.
To see the full article, follow this link: https://nej.md/465pj91
https://youtu.be/DTOcV8uFZyw?si=M6TmFn0zppdpHP_u
🆔 @
.
Читать полностью…
4554